Espervita
Espervita Therapeutics is focused on the discovery of metabolic reprogramming therapies, with a lead program developing first-in-class acetyl-CoA metabolic enzyme inhibitors with beneficial effects across a range of metabolic disease conditions. The company is led by a team with deep expertise in metabolic dysfunction and broad experience in drug discovery and development.
About EspervitaApproach
Acetyl-CoA links carbohydrate and fat metabolism and serves as a primary building block for fatty acids, triglycerides, and cholesterol. Aberrant production and utilization of acetyl-CoA is a driver of metabolic-dysfunction associated steatohepatitis (MASH), chronic kidney disease (CKD), and fibrotic remodeling in the liver and kidney. Espervita's lead compound, EVT0185, is a first-in-class, liver- and kidney-selective inhibitor of acetyl-CoA metabolic enzymes that demonstrates broad efficacy in preclinical models—lowering blood glucose and lipid synthesis, reversing MASH and liver fibrosis, preserving kidney function, and decreasing HCC tumor burden.
ScienceOur Team
Espervita Therapeutics is focused on the discovery of therapies in areas with significant unmet medical need. The company is led by a team with deep expertise in metabolic reprogramming and broad experience in drug discovery and development.
About